title: PKC-mediated toxicity of elevated glucose concentration on cardiomyocyte function.
abstract: While it is well established that mortality risk after myocardial infarction (MI) increases in proportion to blood glucose concentration at the time of admission, it is unclear whether there is a direct, causal relationship. We investigated potential mechanisms by which increased blood glucose may exert cardiotoxicity. Using a Wistar rat or guinea-pig isolated cardiomyocyte model, we investigated the effects on cardiomyocyte function and electrical stability of alterations in extracellular glucose concentration. Contractile function studies using electric field stimulation (EFS), patch-clamp recording, and Ca2+ imaging were used to determine the effects of increased extracellular glucose concentration on cardiomyocyte function. Increasing glucose from 5 to 20 mM caused prolongation of the action potential and increased both basal Ca2+ and variability of the Ca2+ transient amplitude. Elevated extracellular glucose concentration also attenuated the protection afforded by ischemic preconditioning (IPC), as assessed using a simulated ischemia and reperfusion model. Inhibition of PKCα and β, using Gö6976 or specific inhibitor peptides, attenuated the detrimental effects of glucose and restored the cardioprotected phenotype to IPC cells. Increased glucose concentration did not attenuate the cardioprotective role of PKCε, but rather activation of PKCα and β masked its beneficial effect. Elevated extracellular glucose concentration exerts acute cardiotoxicity mediated via PKCα and β. Inhibition of these PKC isoenzymes abolishes the cardiotoxic effects and restores IPC-mediated cardioprotection. These data support a direct link between hyperglycemia and adverse outcome after MI. Cardiac-specific PKCα and β inhibition may be of clinical benefit in this setting.
authors.forename: Mark W
authors.initials: MW
authors.lastname: Sims
authors.forename: James
authors.initials: J
authors.lastname: Winter
authors.forename: Sean
authors.initials: S
authors.lastname: Brennan
authors.forename: Robert I
authors.initials: RI
authors.lastname: Norman
authors.forename: G André
authors.initials: GA
authors.lastname: Ng
authors.forename: Iain B
authors.initials: IB
authors.lastname: Squire
authors.forename: Richard D
authors.initials: RD
authors.lastname: Rainbow
mesh_terms: D000200:Action Potentials; D000818:Animals; D020013:Calcium Signaling; D002478:Cells, Cultured; D005947:Glucose / Q000633:toxicity*; D006352:Heart Ventricles / Q000166:cytology / Q000378:metabolism; D019157:Ischemic Preconditioning, Myocardial; D007527:Isoenzymes / Q000378:metabolism; D008297:Male; D009200:Myocardial Contraction; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000628:therapy; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D011493:Protein Kinase C / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D007527:Isoenzymes; D011493:Protein Kinase C; D005947:Glucose